Table 1 . A decrease occurred in unspecified clinical T classification ( P <.001). The use of MRI as preoperative imaging technique increased ( P <.001) and so did the percentage of patients who were preoperatively discussed in a multidisciplinary team
Search Results
Lieke Gietelink, Michel W.J.M. Wouters, Pieter J. Tanis, Marion M. Deken, Martijn G. ten Berge, Rob A.E.M. Tollenaar, J. Han van Krieken, Mirre E. de Noo, and on behalf of the Dutch Surgical Colorectal Cancer Audit Group
brain MRI.” ➤ 7th bullet was added: “Baseline CRP and serum ferritin.” • Post-CAR T-Cell Infusion: ➤ 1st bullet was revised: “Hospitalization or extremely close outpatient monitoring at centers with transplant or prior outpatient CAR T
-weighted MRI for analysis of in vivo tumor cellularity. Patients are followed up for 5 years after completion of study therapy. Primary Outcome Measures: Determine maximum tolerated dose of vorinostat given in combination with capecitabine and RT
expression and genome-wide copy number using gene, microRNA, and CGH arrays Assess the use of dynamic contrast-enhanced MRI in STS evaluation. Contacts: William Tap, MD • 212-639-5720 Gary Schwartz, MD • 212-639-8324 ClinicalTrials
extraction on drug bioavailability. Secondary Objectives: Assess by RECIST clinical responses signals in a broad array of solid tumors. Evaluate whether dynamic contrast enhanced MRI to determine the degree of vascular permeability and PET scan to
patients with cancer by outlining all imaging procedures recommended in the NCCN Guidelines, including radiographs, CT scans, MRI, functional nuclear medicine imaging (PET, SPECT), and ultrasound. NCCN is recognized by Centers for Medicare & Medicaid
on disease stage and histology. All imaging procedures recommended in the NCCN Guidelines, including radiographs, CT scans, MRI, functional nuclear medicine imaging (PET, SPECT), and ultrasound, are included within NCCN Imaging AUC. NCCN Imaging AUC
Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson
imaging modality for diagnosing RCC and evaluating the extent and stage of disease. MDCT has been associated with 91% accuracy for tumor staging and up to 100% accuracy for assessment of venous tumor invasion. 2 With improvements in CT technology, MRI
David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, Yoshimi Anzai, David M. Brizel, Justine Y. Bruce, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Moon Fenton, Robert L. Foote, Thomas Galloway, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks Jr., Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James W. Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Gregory Weinstein, Matthew Witek, Frank Worden, Sue S. Yom, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow
. Initial imaging of the primary site is done with CT and/or MRI. MRI is generally preferred over CT in patients with cranial nerve symptoms or to evaluate cranial nerve involvement or tumors that encroach on the skull base. CT, conversely, is complementary
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Mayer Fishman, Thomas H. Gallagher, John L. Gore, Steven L. Hancock, Michael R. Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, M. Dror Michaelson, Thomas Olencki, Phillip M. Pierorazio, Elizabeth R. Plimack, Bruce G. Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer, and Rashmi Kumar
CT is more accurate than chest radiograph for chest staging. 21 – 23 Abdominal MRI is used to evaluate the inferior vena cava if tumor involvement is suspected, or it can be used instead of CT for detecting renal masses and for staging when contrast
